Brandon Murphy
YOU?
Author Swipe
View article: Characterization of the BRAF interactome identifies BRAF<sup>V600E</sup><=>TP53 interaction in melanoma
Characterization of the BRAF interactome identifies BRAF<sup>V600E</sup><=>TP53 interaction in melanoma Open
Melanoma is a highly aggressive and frequently metastatic cancer with its incidence reported to be on the rise. Although most oncogenic drivers in melanoma converge on activation of the RAS>RAF>MEK>ERK MAPK signaling pathway, not all MAPK-…
View article: BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling
BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling Open
Secretion of ligands of the human epidermal growth factor (EGFR) family of receptors or erythroblastic leukemia viral oncogene family (ERBB1-4) is a feature common to many cancer cells. However, our understanding of the role of autocrine l…
View article: The OSUMMER lines: A series of ultraviolet‐accelerated NRAS‐mutant mouse melanoma cell lines syngeneic to C57BL/6
The OSUMMER lines: A series of ultraviolet‐accelerated NRAS‐mutant mouse melanoma cell lines syngeneic to C57BL/6 Open
An increasing number of cancer subtypes are treated with front‐line immunotherapy. However, approaches to overcome primary and acquired resistance remain limited. Preclinical mouse models are often used to investigate resistance mechanisms…
View article: Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Mutationally activated BRAF is detected in approximately 7% of human lung adenocarcinomas, with BRAFT1799A serving as a predictive biomarker for treatment of patients with FDA-approved inhibitors of BRAFV600E oncoprotein signaling. In gene…
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Mutationally activated BRAF is detected in approximately 7% of human lung adenocarcinomas, with BRAFT1799A serving as a predictive biomarker for treatment of patients with FDA-approved inhibitors of BRAFV600E oncoprotein signaling. In gene…
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF<sup>V600E</sup>-Driven Lung Tumorigenesis Open
Supplementary Data from Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
View article: The OSUMMER lines: a series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6
The OSUMMER lines: a series of ultraviolet-accelerated NRAS-mutant mouse melanoma cell lines syngeneic to C57BL/6 Open
An increasing number of cancer subtypes are treated with front-line immunotherapy. However, approaches to overcome primary and acquired resistance remain limited. Pre-clinical mouse models are often used to investigate resistance mechanism…
View article: Cell‐intrinsic melanin fails to protect melanocytes from ultraviolet‐mutagenesis in the absence of epidermal melanin
Cell‐intrinsic melanin fails to protect melanocytes from ultraviolet‐mutagenesis in the absence of epidermal melanin Open
Melanin is a free‐radical scavenger, antioxidant, and broadband absorber of ultraviolet (UV) radiation which protects the skin from environmental carcinogenesis. However, melanin synthesis and UV‐induced reactive melanin species are also i…
View article: Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis Open
Mutationally activated BRAF is detected in approximately 7% of human lung adenocarcinomas, with BRAFT1799A serving as a predictive biomarker for treatment of patients with FDA-approved inhibitors of BRAFV600E oncoprotein signaling. In gene…
View article: Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation Open
A distinct profile of NRAS mutants is observed in each tumor type. It is unclear whether these profiles are determined by mutagenic events or functional differences between NRAS oncoproteins. Here, we establish functional hallmarks of NRAS…
View article: Evaluation of websites of state public health agencies during the\n COVID-19 pandemic demonstrating the degree of effort to design for\n accessibility
Evaluation of websites of state public health agencies during the\n COVID-19 pandemic demonstrating the degree of effort to design for\n accessibility Open
Since the beginning of the pandemic, every state public health agency in the\nUnited States has created and maintained a website dedicated to COVID 19. Our\ngoal was to evaluate these websites for conformity to accessibility guidelines.\nS…
View article: Evaluation of websites of state public health agencies during the COVID-19 pandemic demonstrating the degree of effort to design for accessibility
Evaluation of websites of state public health agencies during the COVID-19 pandemic demonstrating the degree of effort to design for accessibility Open
Since the beginning of the pandemic, every state public health agency in the United States has created and maintained a website dedicated to COVID 19. Our goal was to evaluate these websites for conformity to accessibility guidelines. Spec…
View article: UVB mutagenesis differs in <i>Nras</i>- and <i>Braf</i>-mutant mouse models of melanoma
UVB mutagenesis differs in <i>Nras</i>- and <i>Braf</i>-mutant mouse models of melanoma Open
BRAF -mutant melanomas are more likely than NRAS -mutant melanomas to arise in anatomical locations protected from chronic sun damage. We hypothesized that this discrepancy in tumor location is a consequence of the differential sensitivity…
View article: Functional differences drive the selection of NRAS mutants in melanoma
Functional differences drive the selection of NRAS mutants in melanoma Open
Distinct NRAS mutants are enriched in various tumor types. Here, we generated a suite of fully congenic, conditional, Nras knock-in mouse models ( LSL-Nras Q61R, -K, -L, -H, -P, -Q; G12D and G13D, -R ) to test the hypothesis that melanocyt…
View article: UVB mutagenesis differs in <i>NRAS</i>- and <i>BRAF</i>-mutant mouse models of melanoma
UVB mutagenesis differs in <i>NRAS</i>- and <i>BRAF</i>-mutant mouse models of melanoma Open
BRAF -mutant melanomas are more likely than NRAS -mutant melanomas to arise in anatomical locations protected from chronic sun damage. We hypothesized that this discrepancy in tumor location is a consequence of the differential sensitivity…
View article: Rapid Generation of Primary Murine Melanocyte and Fibroblast Cultures
Rapid Generation of Primary Murine Melanocyte and Fibroblast Cultures Open
Defects in fibroblast or melanocyte function are associated with skin diseases, including poor barrier function, defective wound healing, pigmentation defects and cancer. Vital to the understanding and amelioration of these diseases are ex…
View article: Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis
Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis Open
Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) are highly related retroviruses that transform T cells in vitro but have distinct pathological outcomes in vivo . HTLV-1 encodes a protein from the antisense strand of its pro…